Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is a company with strong fundamental reasons supporting its positive outlook. It has delivered consistent and strong financial results, with a 21% increase in ARR and an 18% increase in revenue year-over-year. The company's growth is expected to continue, with strong guidance for ARR and revenue growth in the upcoming year. In addition, its strong focus on the public sector and high recurring revenue from this segment provides stability and potential for long-term growth. The recent acquisition of Corellium also presents potential for future growth and expansion into new markets.

Bears say

Cellebrite DI is facing potential risks and challenges concerning the negative sentiment surrounding law enforcement, as well as challenges with cross-selling and upselling existing customers for future growth. Additionally, the company may face challenges regarding privacy rights and breaches of data security. Despite strong demand and growth drivers, the company's stock may be impacted by the current political and social climate, as well as potential risks in the technology industry.

CLBT has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLBT has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.